Robert S. Landsman

Array ( [id] => 17260049 [patent_doc_number] => 20210373034 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-02 [patent_title] => Methods of Assigning a COVID Pathological Type and Compositions for Practicing the Same, and Methods of Treating a Subject for Chronic COVID-19 [patent_app_type] => utility [patent_app_number] => 17/351055 [patent_app_country] => US [patent_app_date] => 2021-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18637 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17351055 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18468867 [patent_doc_number] => 20230203150 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-29 [patent_title] => Methods and Treatment Involving Antibodies to IL-18 [patent_app_type] => utility [patent_app_number] => 17/928427 [patent_app_country] => US [patent_app_date] => 2021-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16338 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17928427 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19571888 [patent_doc_number] => 20240376180 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-14 [patent_title] => HUMAN RECOMBINANT MONOCLONAL ANTIBODY AGAINST SARS-COV-2 SPIKE GLYCOPROTEIN [patent_app_type] => utility [patent_app_number] => 17/928013 [patent_app_country] => US [patent_app_date] => 2021-05-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32423 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17928013 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18530019 [patent_doc_number] => 20230235087 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-27 [patent_title] => ANTI-GD2 SADA CONJUGATES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/999786 [patent_app_country] => US [patent_app_date] => 2021-05-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32497 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17999786 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18420196 [patent_doc_number] => 20230174657 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-08 [patent_title] => COMPOSITIONS COMPRISING AN ANTIBODY AGAINST INTERLEUKIN-6 RECEPTOR FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME [patent_app_type] => utility [patent_app_number] => 17/926018 [patent_app_country] => US [patent_app_date] => 2021-05-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16175 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17926018 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18484985 [patent_doc_number] => 20230212300 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-06 [patent_title] => HUMAN ENDOTHELIN RECEPTOR A (ETAR) ANTAGONIST ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/926295 [patent_app_country] => US [patent_app_date] => 2021-05-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32630 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17926295 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18093180 [patent_doc_number] => 20220411521 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-29 [patent_title] => POLYPEPTIDES THAT BIND GLUCOCORTICOID-INDUCED TNFR FAMILY-RELATED RECEPTOR (GITR) [patent_app_type] => utility [patent_app_number] => 17/320395 [patent_app_country] => US [patent_app_date] => 2021-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 63559 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17320395 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18931001 [patent_doc_number] => 11883395 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-30 [patent_title] => Method of treating severe acute respiratory syndrome (SARS) virus infection by administering a protein disulfide isomerase (PDI) inhibitor [patent_app_type] => utility [patent_app_number] => 17/320069 [patent_app_country] => US [patent_app_date] => 2021-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 3 [patent_no_of_words] => 11915 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17320069 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18932329 [patent_doc_number] => 11884736 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-30 [patent_title] => Antibodies which bind to glucagon-like peptide 1 receptor (GLP1R) [patent_app_type] => utility [patent_app_number] => 17/317056 [patent_app_country] => US [patent_app_date] => 2021-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 20177 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17317056 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17085264 [patent_doc_number] => 20210280271 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-09 [patent_title] => DEVELOPING CLASSIFIERS FOR STRATIFYING PATIENTS [patent_app_type] => utility [patent_app_number] => 17/315580 [patent_app_country] => US [patent_app_date] => 2021-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35579 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17315580 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17990452 [patent_doc_number] => 20220356489 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-10 [patent_title] => COMPOSITIONS AND METHODS FOR REGULATING PRODUCTION OF AN EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITOR [patent_app_type] => utility [patent_app_number] => 17/313801 [patent_app_country] => US [patent_app_date] => 2021-05-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6071 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17313801 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20358333 [patent_doc_number] => 12474324 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-18 [patent_title] => Method of making an aromagraph comprising ectopic olfactory receptors [patent_app_type] => utility [patent_app_number] => 17/308743 [patent_app_country] => US [patent_app_date] => 2021-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 14739 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 165 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17308743 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17170370 [patent_doc_number] => 20210324040 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-21 [patent_title] => TGF-BETA RECEPTOR TYPE II FUSION PROTEINS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/245581 [patent_app_country] => US [patent_app_date] => 2021-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29912 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17245581 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18056400 [patent_doc_number] => 20220387486 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-08 [patent_title] => NUCLEIC ACID MOLECULES ENCODING CHIMERIC ANTIGEN RECEPTORS COMPRISING A CD20 BINDING DOMAIN [patent_app_type] => utility [patent_app_number] => 17/246351 [patent_app_country] => US [patent_app_date] => 2021-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 129467 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17246351 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18405828 [patent_doc_number] => 20230167179 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-01 [patent_title] => ANTIBODY AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/921792 [patent_app_country] => US [patent_app_date] => 2021-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12064 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17921792 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18468878 [patent_doc_number] => 20230203161 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-29 [patent_title] => MULTISPECIFIC HEAVY CHAIN ANTIBODIES WITH MODIFIED HEAVY CHAIN CONSTANT REGIONS [patent_app_type] => utility [patent_app_number] => 17/997241 [patent_app_country] => US [patent_app_date] => 2021-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30842 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -58 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17997241 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18484999 [patent_doc_number] => 20230212317 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-06 [patent_title] => HETERODIMERIC PROTEINS [patent_app_type] => utility [patent_app_number] => 17/996728 [patent_app_country] => US [patent_app_date] => 2021-04-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23614 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -46 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17996728 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18995935 [patent_doc_number] => 11912762 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-02-27 [patent_title] => Method of treating osteoarthritis by administering an anti-connexin 43 antibody [patent_app_type] => utility [patent_app_number] => 17/234315 [patent_app_country] => US [patent_app_date] => 2021-04-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 22 [patent_no_of_words] => 11453 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17234315 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16991832 [patent_doc_number] => 20210230252 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-29 [patent_title] => TGF-BETA RECEPTOR TYPE II VARIANTS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/229132 [patent_app_country] => US [patent_app_date] => 2021-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29542 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17229132 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18666283 [patent_doc_number] => 11773161 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-03 [patent_title] => Anti-bril antibody [patent_app_type] => utility [patent_app_number] => 17/226312 [patent_app_country] => US [patent_app_date] => 2021-04-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 6 [patent_no_of_words] => 21484 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17226312 [rel_patent_id] =>[rel_patent_doc_number] =>)